Maher Masoud starts as MaxCyte president, CEO

MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.

The AIM-traded firm said that alongside his role as CEO, Masoud had joined its board of directors.

With the appointment, MaxCyte was aiming to leverage Masoud's leadership and experience to continue its mission of advancing the field of cell therapeutics and bioprocessing.

At 0813 GMT, shares in MaxCyte were down 0.14% at 352p.

Reporting by Josh White for Sharecast.com.